Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Guggenheim Maintains Buy on Blueprint Medicines, Raises Price Target to $138

Author: Benzinga Newsdesk | August 02, 2024 03:10pm

Guggenheim analyst Michael Schmitz maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $130 to $138.

Posted In: BPMC